Welllight Cream is a topical formulation containing Hydroquinone (2% w/w), Mometasone (0.1% w/w), and Tretinoin (0.025% w/w), designed for the treatment of hyperpigmentation disorders such as melasma, post-inflammatory hyperpigmentation, and other pigmentary abnormalities. Hydroquinone acts as a skin-lightening agent by inhibiting tyrosinase, an enzyme crucial for melanin synthesis, thereby reducing excessive pigmentation. Mometasone, a potent corticosteroid, provides anti-inflammatory effects that help to alleviate erythema, swelling, and irritation associated with pigmentary conditions, enhancing the overall efficacy of the treatment. Tretinoin, a retinoid, promotes epidermal cell turnover and exfoliation, facilitating the removal of pigmented keratinocytes and improving skin texture and tone. The combination of these active ingredients offers a synergistic approach to managing hyperpigmentation by targeting melanin production, inflammation, and epidermal renewal. Welllight Cream should be applied once daily to the affected areas as directed by a healthcare professional, avoiding contact with eyes and mucous membranes. Patients are advised to use sunscreen and limit sun exposure during treatment to prevent exacerbation of pigmentation. Caution is warranted in individuals with sensitive skin or known hypersensitivity to any component. Use under medical supervision is recommended to monitor for potential side effects such as skin irritation or corticosteroid-related adverse effects.